Primary Pulmonary Lymphoma with Superior Vena Cava Syndrome
Biomolecular and Health Science Journal · 2018
DOI: 10.20473/bhsj.v1i2.9858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecular and Health Science Journal, 2018. Verfasst von Alfian Nur Rosyid und 1 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Primary Pulmonary Lymphoma (PPL) is a clonal proliferation of lymphoid cells that involve one or two lungs (parenchyma and or bronchi. PPL is found in approximately 0.4% of all lymphoma cases and 3.6% of NHL cases. Five years survival rate at stage I and II is 90%, and 80% in stage III and IV. A 63-year-old male farmer presented with chief complaint of shortness of breath for one week before admission and preceded by coughing for a month, loss of appetite and night sweating. There was an abnormal physical examination on the right side of the chest with non-tender lymph node enlargements in the right supraclavicular and neck region and superior vena cava syndrome. CT guided FNAB suggesting NHL. Patient was treated with CHOP chemotherapy regiment. However, with high grade lymphoma, patient did not respond well.
Zitieren
APA
Rosyid, A. N., & Meliana, R. Y. (2018). Primary Pulmonary Lymphoma with Superior Vena Cava Syndrome. Biomolecular and Health Science Journal. https://doi.org/10.20473/bhsj.v1i2.9858
Vancouver
Rosyid AN, Meliana RY. Primary Pulmonary Lymphoma with Superior Vena Cava Syndrome. Biomolecular and Health Science Journal. 2018. doi:10.20473/bhsj.v1i2.9858
BibTeX
@article{Rosyid2018,
author = {Rosyid, Alfian Nur and Meliana, Resti Yudhawati},
title = {Primary Pulmonary Lymphoma with Superior Vena Cava Syndrome},
journal = {Biomolecular and Health Science Journal},
year = {2018},
doi = {10.20473/bhsj.v1i2.9858}
}
EUVIMED